Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00406-025-02066-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mentalization and Emotional-Cognitive Rigidity as predictors of esketamine's effects on Treatment-Resistant Depression: Findings from a prospective observational study.
J Affect Disord
September 2025
Department of Mental Health and Addiction Services, ASST Fatebenefratelli-Sacco, Milan, Italy; Department of Mental Health, Department of Biomedical and Clinical Sciences "Luigi Sacco", University of Milan, Milan, Italy; "Aldo Ravelli" Center for Nanotechnology and Neurostimulation, University of Mi
Introduction: Treatment-Resistant Depression (TRD) remains a major challenge in the management of Major Depressive Disorder (MDD). Esketamine, the S-enantiomer of ketamine and a glutamatergic modulator, has been approved by the FDA and EMA for TRD in 2019. Beyond its rapid antidepressant effects, esketamine may enhance neuroplasticity, facilitating the reconnection with emotional and cognitive processes, improving mentalization, social cognition and promoting resilience.
View Article and Find Full Text PDFNew and emerging pharmacologic treatments for MDD.
Front Psychiatry
August 2025
Standardization of Computational Anatomy Techniques for Cognitive and Behavioral Sciences (SoCAT) Lab, Department of Psychiatry, Faculty of the Medicine, Ege University, Izmir, Türkiye.
Major depressive disorder (MDD) presents a significant global health challenge, characterized by a high prevalence and significant impact on quality of life. Traditional antidepressants fall short in terms of efficacy and onset speed, up to 60% of patients. This review delves into the new and emerging pharmacologic treatments for MDD, focusing on their mechanisms of action, clinical effectiveness, and potential to fill the gaps left by conventional therapies.
View Article and Find Full Text PDFKetamine - mechanisms of action as an antidepressant.
Psychiatr Pol
June 2025
Klinika Psychiatrii Dorosłych 91-229 Łódź, ul. Aleksandrowska 159.
Since the year 2000, ketamine and its enantiomers have been studied for their antidepressant effects. This paper will briefly summarise the journey of ketamine from an anaesthetic to an antidepressant. The text will present the key mechanisms of its action, as well as the actions of its metabolites.
View Article and Find Full Text PDFEffect of ketamine and esketamine on RNA expression and its relevance for depression: A systematic review.
Pharmacol Res
September 2025
Department of Molecular and Translational Medicine, University of Brescia, Brescia 25123, Italy; Genetics Unit, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia 25125, Italy. Electronic address:
Treatment-resistant depression (TRD) remains a challenge in psychiatry, necessitating novel therapeutic strategies beyond traditional monoaminergic antidepressants. Ketamine and its S-enantiomer esketamine have demonstrated rapid and robust antidepressant effects in TRD, probably through mechanisms involving glutamatergic modulation, neuroplasticity, and anti-inflammatory properties. However, the molecular underpinnings of these effects are not yet understood.
View Article and Find Full Text PDFKetamine and its enantiomers in treatment-resistant depression: promise, pitfalls, and personalized psychiatry.
Eur Arch Psychiatry Clin Neurosci
August 2025
Chiba University Center for Forensic Mental Health, 1-8-1 Inohana, Chiba, 260-8670, Japan.